Warrant

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

Friday, June 5, 2020 - 9:01pm

The offering was comprised of 14,601,628 shares of common stock, together with Series H Warrants to purchase 8,695,664 shares of common stock.

Key Points: 
  • The offering was comprised of 14,601,628 shares of common stock, together with Series H Warrants to purchase 8,695,664 shares of common stock.
  • The public offering price of a share of Common Stock together with one-half of a Series H Warrant to purchase one share of common stock was $1.15.
  • The shares of common stock and the accompanying Series H warrants were purchased together in this offering but were issued separately.
  • The pre-funded warrant and the accompanying Series H Warrants were purchased together in the offering but were issued separately.

ARYA Sciences Acquisition Corp II Announces Pricing of $130 Million Initial Public Offering

Friday, June 5, 2020 - 4:54am

NEW YORK, NY, June 04, 2020 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp II (the Company), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, today announced the pricing of its initial public offering of 13,000,000 units at a price of $10.00 per unit.

Key Points: 
  • NEW YORK, NY, June 04, 2020 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp II (the Company), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, today announced the pricing of its initial public offering of 13,000,000 units at a price of $10.00 per unit.
  • Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share.
  • The Company has granted the underwriters a 45-day option to purchase up to an additional 1,950,000 units to cover over-allotments, if any, at the initial public offering price.
  • This press release contains statements that constitute forward-looking statements, including with respect to the proposed initial public offering and the anticipated use of the net proceeds.

Roth CH Acquisition I Co. Announces the Separate Trading of its Common Stock and Warrants, Commencing June 11, 2020

Thursday, June 4, 2020 - 9:00pm

No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

Key Points: 
  • No fractional warrants will be issued upon separation of the units and only whole warrants will trade.
  • The shares of common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols ROCH and ROCHW, respectively.
  • Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol ROCHU.
  • Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Companys transfer agent, in order to separate the units into shares of common stock and warrants.

FSD Pharma Inc. Announces C$10.125 Million Private Placement

Thursday, June 4, 2020 - 2:40pm

FSD Pharma Inc. (NASDAQ: HUGE) (FSD Pharma or the Company), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Companys Class B Subordinate Voting Shares (Shares) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million.

Key Points: 
  • FSD Pharma Inc. (NASDAQ: HUGE) (FSD Pharma or the Company), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Companys Class B Subordinate Voting Shares (Shares) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million.
  • The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company.
  • The proceeds are expected to be used for working capital and other general corporate purposes.
  • FSD Pharma Inc. (Nasdaq: HUGE; CSE: HUGE.CN; FRA: 0K9A) is a publicly traded holding company, since May 2018.

Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million

Thursday, June 4, 2020 - 2:00pm

Following the earlier issuance to Strul of a convertible note in the principal amount of US$4 million and 2,573,959 warrants (the Warrants), the Company has raised aggregate gross proceeds of US$5 million (the Offering).

Key Points: 
  • Following the earlier issuance to Strul of a convertible note in the principal amount of US$4 million and 2,573,959 warrants (the Warrants), the Company has raised aggregate gross proceeds of US$5 million (the Offering).
  • The 2020 Notes have a maturity date of 48-months after issuance with a holders option for early redemption at 24-months.
  • Neovasc intends to use the net proceeds from the Offering for the development and commercialization of the Neovasc Reducer (the "Reducer"), development of the Tiara (the "Tiara") and general corporate and working capital purposes.
  • Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

CloudMD Announces Commencement of Trading on the TSX Venture Exchange

Thursday, June 4, 2020 - 12:30pm

The Companys common shares have been delisted from the Canadian Securities Exchange.

Key Points: 
  • The Companys common shares have been delisted from the Canadian Securities Exchange.
  • Further to the Companys news release of June 2, 2020, the Company issued 10,678,900 warrants (the Warrants) on the Canadian Securities Exchange.
  • The Warrants will continue to be listed on the Canadian Securities Exchange under CUSIP 18912C136 until further notice.
  • CloudMD currently provides service to a combined ecosystem of 376 clinics, over 3000 licensed practitioners and almost 3 million patient charts across its servers.

Cansortium Inc. Announces Issuance of Shares for Directors' Fees

Wednesday, June 3, 2020 - 9:42pm

The Company is issuing 408,286 common shares at a deemed price of U.S.$0.38 per share in satisfaction of U.S.$155,149 of accrued directors' fees with the balance being paid in cash.

Key Points: 
  • The Company is issuing 408,286 common shares at a deemed price of U.S.$0.38 per share in satisfaction of U.S.$155,149 of accrued directors' fees with the balance being paid in cash.
  • Issuing shares instead of making a cash payment, in satisfaction of a portion of accrued directors' fees, will assist the Company in preserving cash for deployment on actionable growth opportunities.
  • The issuance of common shares to each of Neal Hochberg and John McKimm constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101").
  • Cansortium Inc.'s common shares and warrants trade on the CSE under the symbol "TIUM.U" and "TIUM.WT.U", respectively, and on the OTCQB Venture Market under the symbol (OTCQB: CNTMF).

AMERI Holdings Announces Pricing Of $1.725 Million Registered Direct Offering Priced At-The-Market

Wednesday, June 3, 2020 - 1:30pm

ATLANTA, June 3, 2020 /PRNewswire/ --AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately$1.725 millionof its common shares in a registered direct offering priced at-the-market under Nasdaq rules.

Key Points: 
  • ATLANTA, June 3, 2020 /PRNewswire/ --AMERI Holdings, Inc. (NASDAQ: AMRH) (the "Company"), today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately$1.725 millionof its common shares in a registered direct offering priced at-the-market under Nasdaq rules.
  • The gross proceeds to the Company from the registered direct offering is expected to be approximately$1.725 millionbefore deducting fees and other estimated offering expenses.
  • The registered direct offering is expected to close on or aboutJune 5, 2020, subject to the satisfaction of customary closing conditions.
  • The common shares and pre-funded warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No.

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

Wednesday, June 3, 2020 - 2:00pm

FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of $20.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of $20.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.
  • The offering is priced at a public offering price of $1.15 per share of common stock and one-half of a Series H Warrant.
  • This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering.
  • The offering is being made solely by means of a prospectus.A final prospectus relating to this offering will be filed by Cellectar with the SEC.

Siyata Mobile Announces Non-Brokered Private Placement of ~$1.0M USD in Unsecured Convertible Debentures

Wednesday, June 3, 2020 - 1:00pm

Each Convertible Debenture will bear interest at a rate of 10.0% per annum from the date of issue, payable in cash quarterly in arrears.

Key Points: 
  • Each Convertible Debenture will bear interest at a rate of 10.0% per annum from the date of issue, payable in cash quarterly in arrears.
  • Any unpaid interest payments will accrue and be added to the principal amount of the Convertible Debenture.
  • On the closing date, Accel will also receive one (1) non-transferrable common share purchase warrant (each, a Warrant) for each CDN$1.00 principal amount of the Convertible Debentures purchased.
  • Siyata Mobile Inc. is a B2B global vendor of next generation Push-To-Talk over Cellular (PTT) devices and cellular booster systems.